Peritoneovenous shunts in patients with intractable ascites: palliation at what price?
Intractable ascites carries great morbidity by affecting appetite, mobility, and quality of life. Peritoneovenous shunts (PVSs) are utilized to abate intractable ascites, although long-term efficacy is unestablished. Thirty male and 18 female cirrhotics, 55 +/- 12 (standard deviation) years of age, failed multiple large-volume paracenteses and diuretic therapy before undergoing PVS. Data were collected until death or the present time. Nine patients (19%) are alive and palliated, four with working shunts [average follow-up (ave. f/u), 30 months] and five without shunts (ave. f/u, 19 months). Thirty-two (67%) patients died: 18 palliated with functional shunts (survival time, 4.4 +/- 5.7 months), 8 unpalliated with dysfunctional shunts (ave. f/u, 3.9 +/- 4.5 months), 4 unpalliated with shunts removed (ave. f/u 5.5 +/- 4.7 months), and 2 with unknown shunt function at death. Function was lost to occlusion in 26 patients, infection in 9, and ligation for disseminated intravascular coagulation in 3. Thirteen patients underwent 18 shunt replacements. At death/present time, 22 (46%) patients were palliated with functioning shunts. Seven patients were lost to follow-up. PVSs provide palliation for intractable ascites short term, but commonly occlude within 1 year. Despite palliation, complications with PVSs are high, and survival is limited.
Zervos
E E
EE
University of South Florida, Tampa, USA.
McCormick
J
J
Goode
S E
SE
Rosemurgy
A S
AS
D001201:Ascites / Q000209:etiology / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000601:surgery; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010536:Peritoneovenous Shunt / Q000009:adverse effects / Q000401:mortality; D011183:Postoperative Complications / Q000401:mortality*; D013997:Time Factors; D016896:Treatment Outcome